Article
Microbiology
Maria Milagro Montero, Sandra Domene-Ochoa, Carla Lopez-Causape, Inmaculada Lopez-Montesinos, Sonia Luque, Luisa Sorli, Nuria Campillo, Eduardo Padilla, Nuria Prim, Lorena Ferrer Alapont, Santiago Grau, Antonio Oliver, Juan P. Horcajada
Summary: This study compared the efficacy of intermittent, extended, and continuous infusion of ceftolozane-tazobactam (C/T) and found that continuous infusion achieved the best results in treating infections caused by extensively drug-resistant (XDR) P. aeruginosa isolates. It was the only regimen with bactericidal activity against all tested isolates, indicating the potential of continuous C/T infusion as a treatment option.
MICROBIOLOGY SPECTRUM
(2022)
Article
Infectious Diseases
David P. Nicolau, Jan De Waele, Joseph L. Kuti, Luzelena Caro, Kajal B. Larson, Brian Yu, Elaine Gadzicki, Zhen Zeng, Elizabeth G. Rhee, Matthew L. Rizk
Summary: This study aimed to determine the adequacy of established ceftolozane/tazobactam dosing for patients with augmented renal clearance (ARC) and bacterial infection. The results showed that a 3 g C/T dose met pharmacodynamic targets for ceftolozane and tazobactam in patients with ARC, with mild to moderate treatment-emergent adverse events observed.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Review
Infectious Diseases
Marco Fiore, Antonio Corrente, Maria Caterina Pace, Aniello Alfieri, Vittorio Simeon, Mariachiara Ippolito, Antonino Giarratano, Andrea Cortegiani
Summary: According to this systematic review and meta-analysis, C/T combination therapy is more effective in treating severe infections compared to C/T monotherapy, resulting in a reduction in patient mortality. However, there were no significant differences between C/T combination therapy and C/T monotherapy in terms of clinical improvement and microbiological cure.
Article
Infectious Diseases
S. Alexander Winans, Richelle L. Guerrero-Wooley, Susie H. Park, Garret Hino, Steven C. Forland
Summary: Ceftolozane-tazobactam has been approved for treating multidrug-resistant Pseudomonas aeruginosa meningitis, with cerebrospinal fluid concentrations reaching 83% of serum levels. Combined with other antibiotics, treatment led to clearance of the organism from the patient's cerebrospinal fluid and significant reduction in inflammatory cells.
Article
Infectious Diseases
Christian M. Gill, David P. Nicolau, RACE PA Global Study Grp
Summary: This study evaluated the genotypic and ceftazidime/avibactam-susceptibility profiles of ceftolozane/tazobactam-non-susceptible, MBL-negative Pseudomonas aeruginosa. The results showed that ceftazidime/avibactam remained active against the majority of ceftolozane/tazobactam-non-susceptible, MBL-negative Pseudomonas aeruginosa.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Barbara Balandin, Daniel Ballesteros, Rafael Ruiz de Luna, Loreto Lopez-Vergara, Vicente Pintado, Milagros Sancho-Gonzalez, Cruz Soriano-Cuesta, Maria Jose Perez-Pedrero, Maria Jose Asensio-Martin, Inamculada Fernandez-Simon, Diego Rodriguez-Serrano, Alberto Silva, Marta Chicot, Reyes Iranzo, Fernando Martinez-Sagasti, Ana Royuela
Summary: This study assessed the efficacy of ceftolozane-tazobactam (C/T) in treating Pseudomonas aeruginosa infections in critically ill patients. Results showed that C/T was effective in treating severe infections, with outcomes mainly related to infection severity. High-dose C/T or combination therapy with other antibiotics did not show additional benefits.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Review
Public, Environmental & Occupational Health
Laura Puzniak, Ryan Dillon, Thomas Palmer, Hannah Collings, Ashley Enstone
Summary: The review shows that Ceftolozane/tazobactam (C/T) is effective in clinical practice for gram-negative infections, even in seriously ill patients with resistant pathogens. Comparative studies suggest that C/T is a successful alternative to standard of care (SoC), with similar or better outcomes compared to other regimens.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
(2021)
Article
Microbiology
Abigail M. Rubio, Ellen G. Kline, Chelsea E. Jones, Liang Chen, Barry N. Kreiswirth, M. Hong Nguyen, Cornelius J. Clancy, Vaughn S. Cooper, Ghady Haidar, Daria Van Tyne, Ryan K. Shields
Summary: In this study, we compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates before and after exposure to ceftolozane-tazobactam and found treatment-emergent mutations in the AmpC gene, which were associated with altered resistance patterns. However, some ceftolozane-tazobactam-resistant isolates with AmpC mutations remained susceptible to imipenem-relebactam.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Damien Fournier, Romain Carriere, Maxime Bour, Emilie Grisot, Pauline Triponney, Cedric Muller, Jerome Lemoine, Katy Jeannot, Patrick Plesiat
Summary: This study evaluated the resistance mechanisms of Pseudomonas aeruginosa to ceftolozane/tazobactam, identifying strains with various resistance genes and high production of cephalosporinase PDC. It also found mutations in regulatory genes and enzymes contributing to resistance, highlighting the importance of both intrinsic and transferable mechanisms in C/T-resistant P. aeruginosa.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Jocelyn Qi-Min Teo, Jie Chong Lim, Cheng Yee Tang, Shannon Jing-Yi Lee, Si Hui Tan, James Heng-Chiak Sim, Rick Twee-Hee Ong, Andrea Lay-Hoon Kwa
Summary: This study analyzed 195 carbapenem-nonsusceptible Pseudomonas aeruginosa clinical isolates recovered in Singapore from 2009 to 2020, and found that resistance to ceftolozane/tazobactam was mainly mediated by beta-lactamases, especially metallo-beta-lactamases. The high resistance to C/T highlights its limited utility as an empirical agent in the region.
Article
Infectious Diseases
Anis Karuniawati, Merry Ambarwulan, Selvi Nafisa Shahab, Yefta Moenadjat, Toar J. M. Lalisang, Neneng Dewi Kurniati, Vicky Sumarki Budipramana, Tomy Lesmana, Iva Puspitasari, Erik Prabowo, Dwi Putranti Chitra Sasmitasari, Dian Oktavianti Putri, Amrilmaen Badawi
Summary: Complicated intra-abdominal infections (cIAIs) can have severe consequences if not properly managed. However, limited microbial pattern and susceptibility data for new antibiotics in Indonesia are available. This study aimed to investigate the in vitro activity of Ceftolozane/tazobactam (C/T) against clinical isolates from cIAI patients. The study found that C/T demonstrated high susceptibility against Gram-negative bacteria, including common pathogens such as E. coli, K. pneumoniae, and P. aeruginosa. C/T also remained effective against ESBL Enterobacterales and carbapenem-non-susceptible P. aeruginosa. These findings suggest that C/T can be considered as a valuable option for the treatment of cIAIs with carbapenem-sparing strategy.
Article
Infectious Diseases
Wei Yu, Hui Zhang, Ying Zhu, PeiYao Jia, YingChun Xu, QiWen Yang
Summary: The in-vitro activity of ceftolozane/tazobactam in combination with other antimicrobial agents against Pseudomonas aeruginosa with different resistance patterns was evaluated in this study. The results showed that ceftolozane/tazobactam exhibited good in-vitro inhibitory activity against Pseudomonas aeruginosa and could be considered as an optional therapeutic agent.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Microbiology
Gabriel Cabot, Kihun Kim, Brian L. L. Mark, Antonio Oliver, Mazdak Khajehpour
Summary: Several mutations in Pseudomonas aeruginosa AmpC have led to higher resistance against ceftazidime and ceftolozane, and also make the bacteria evade inhibition by avibactam. Interestingly, these mutations also make the strains more susceptible to carbapenem. The loss of efficacy in hydrolyzing imipenem by the cephalosporin-resistant AmpC enzymes may be attributed to their increased flexibility and dynamics compared to the wild type.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Microbiology
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Aminah Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Yazed Saleh Alsowaida
Summary: This study aimed to compare the effectiveness and safety of C-T and CAZ-AVI in treating infections caused by resistant P. aeruginosa. The results showed no significant differences between C-T and CAZ-AVI in terms of in-hospital mortality, 30-day mortality, clinical cure, and safety. Both drugs can be potential options for the treatment of MDR P. aeruginosa infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Michael A. Pfaller, Dee Shortridge, Kelly A. Harris, Mark W. Garrison, C. Andrew DeRyke, Daryl D. DePestel, Pamela A. Moise, Helio S. Sader
Summary: This study reported on the activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa isolates from US ICUs, showing that ceftolozane-tazobactam had the greatest activity against resistant phenotypes and DTR isolates.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Mariana Castanheira, Lalitagauri M. Deshpande, Shawn A. Messer, Paul R. Rhomberg, Michael A. Pfaller
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2020)
Article
Microbiology
Mariana Castanheira, Timothy B. Doyle, Valerie Kantro, Rodrigo E. Mendes, Dee Shortridge
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Article
Microbiology
E. Wenzler, K. M. Meyer, S. C. Bleasdale, M. Sikka, R. E. Mendes, K. L. Bunnell, M. Finnemeyer, S. L. Rosenkranz, L. H. Danziger, K. A. Rodvold
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Article
Microbiology
M. Biagi, X. Tan, T. Wu, M. Jurkovic, A. Vialichka, K. Meyer, R. E. Mendes, E. Wenzler
JOURNAL OF CLINICAL MICROBIOLOGY
(2020)
Article
Infectious Diseases
Michael A. Pfaller, Cecilia G. Carvalhaes, Caitlin J. Smith, Daniel J. Diekema, Mariana Castanheira
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
(2020)
Article
Infectious Diseases
Helio S. Sader, Cecilia G. Carvalhaes, Jennifer M. Streit, Mariana Castanheira, Robert K. Flamm
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2020)
Article
Microbiology
Mariana Castanheira, Helio S. Sader, Rodrigo E. Mendes, Ronald N. Jones
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Correction
Microbiology
Mariana Castanheira, Timothy B. Doyle, Valerie Kantro, Rodrigo E. Mendes, Dee Shortridge
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Article
Infectious Diseases
Mariana Castanheira, Timothy B. Doyle, Cecilia G. Carvalhaes, Brieanna M. Roth, Paul R. Rhomberg, Rodrigo E. Mendes
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
(2020)
Article
Infectious Diseases
Rodrigo E. Mendes, Michael D. Huband, Jennifer M. Streit, Mariana Castanheira, Robert K. Flamm
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
(2020)
Article
Infectious Diseases
Mariana Castanheira, Timothy B. Doyle, Cory Hubler, Helio S. Sader, Rodrigo E. Mendes
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2020)
Article
Microbiology
Brian D. Johnston, Paul Thuras, Stephen B. Porter, Melissa Anacker, Brittany VonBank, Paula Snippes Vagnone, Medora Witwer, Mariana Castanheira, James R. Johnson
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)
Article
Microbiology
Rodrigo E. Mendes, Paul R. Rhomberg, Troy Lister, Nicole Cotroneo, Thomas R. Parr, Mariana Castanheira
Summary: The study evaluated the activities of various antibiotics alone and in combination with SPR741 against E. coli and K. pneumoniae isolates, indicating that azithromycin-SPR741 and minocycline-SPR741 had the lowest MIC90 values. Furthermore, fusidic acid-SPR741 showed better inhibition against enzymatic MLS mechanisms.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Helio S. Sader, Leonard R. Duncan, S. J. Ryan Arends, Cecilia G. Carvalhaes, Mariana Castanheira
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2020)